DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 199 filers reported holding DENALI THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,015,144 | -41.8% | 34,400 | -54.6% | 0.00% | -40.0% |
| Q1 2023 | $1,745,073 | -15.7% | 75,741 | +1.8% | 0.01% | -16.7% |
| Q4 2022 | $2,070,037 | -74.2% | 74,435 | -71.5% | 0.01% | -77.8% |
| Q3 2022 | $8,015,000 | +323.4% | 261,170 | +306.0% | 0.03% | +350.0% |
| Q2 2022 | $1,893,000 | +96.2% | 64,324 | +114.4% | 0.01% | +100.0% |
| Q1 2022 | $965,000 | +152.6% | 30,001 | +249.8% | 0.00% | +200.0% |
| Q4 2021 | $382,000 | -93.3% | 8,576 | -92.5% | 0.00% | -92.3% |
| Q3 2021 | $5,735,000 | -66.7% | 113,671 | -48.2% | 0.01% | -66.7% |
| Q2 2021 | $17,211,000 | -39.3% | 219,415 | -55.8% | 0.04% | -47.3% |
| Q1 2021 | $28,362,000 | +29.7% | 496,703 | +90.3% | 0.07% | +17.5% |
| Q4 2020 | $21,867,000 | +219.5% | 261,070 | +36.7% | 0.06% | +162.5% |
| Q3 2020 | $6,845,000 | +125.5% | 191,045 | +52.2% | 0.02% | +60.0% |
| Q2 2020 | $3,036,000 | – | 125,538 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
| Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
| Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
| Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
| MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
| Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
| PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
| HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |